Suppr超能文献

IVB 期伴有远处淋巴转移的宫颈癌放化疗对预后的影响。

Impact of Chemoradiation on Prognosis in Stage IVB Cervical Cancer with Distant Lymphatic Metastasis.

机构信息

Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea.

出版信息

Cancer Res Treat. 2013 Sep;45(3):193-201. doi: 10.4143/crt.2013.45.3.193. Epub 2013 Sep 30.

Abstract

PURPOSE

The purpose of this study was to determine whether chemoradiation (CCR) is efficient for improving prognosis, compared with systemic chemotherapy (SC), in patients with stage IVB cervical cancer who have distant lymphatic metastasis.

MATERIALS AND METHODS

Among 2,322 patients with cervical cancer between January 2000 and March 2010, 43 patients (1.9%) had stage IVB disease. After exclusion of 19 patients due to insufficient data and hematogenous metastasis, 24 patients (1%) who received CCR (n=10) or SC (n=14) were enrolled. We compared tumor response, progression-free survival (PFS) and overall survival (OS), and disease recurrence between CCR and SC.

RESULTS

Complete response rates were 60% and 0% after CCR and SC (p<0.01). Grade 3 or 4 leukopenia was more common in patients treated with CCR (24.4% vs. 9.1%, p=0.03), whereas grade 3 or 4 neuropenia was more frequent in those treated with SC (28.4% vs. 11.1%, p=0.03). Development of grade 3 proctitis occurred as a late radiotherapy (RT)-related toxicity in only one patient (10%) treated with CCR. In addition, squamous cell carcinoma and CCR were favorable prognostic factors for improvement of PFS (adjusted hazard ratios [HRs], 0.17 and 0.12; 95% confidence intervals [CIs], 0.04 to 0.80 and 0.03 to 0.61), and only CCR was significant for improvement of OS (adjusted HR, 0.15; 95% CI, 0.02 to 0.90). However, no differences in the rate and pattern of disease recurrence were observed between CCR and SC.

CONCLUSION

CCR may be more effective than SC for improving survival, and can be regarded as a feasible method with some caution regarding late RT-related toxicity for treatment of stage IVB cervical cancer with distant lymphatic metastasis.

摘要

目的

本研究旨在确定对于存在远处淋巴结转移的 IVB 期宫颈癌患者,与全身化疗(SC)相比,化放疗(CCR)是否能改善预后。

材料和方法

在 2000 年 1 月至 2010 年 3 月期间,2322 例宫颈癌患者中,43 例(1.9%)为 IVB 期疾病。排除 19 例因数据不足和血行转移的患者后,入组了 24 例(1%)接受 CCR(n=10)或 SC(n=14)的患者。我们比较了 CCR 和 SC 之间的肿瘤反应、无进展生存期(PFS)和总生存期(OS)以及疾病复发率。

结果

CCR 治疗后的完全缓解率为 60%,SC 治疗后的完全缓解率为 0%(p<0.01)。CCR 治疗组白细胞减少症 3 或 4 级发生率较高(24.4%比 9.1%,p=0.03),而 SC 治疗组神经毒性 3 或 4 级发生率较高(28.4%比 11.1%,p=0.03)。只有 1 例(10%)接受 CCR 治疗的患者出现晚期放疗(RT)相关的 3 级直肠炎。此外,鳞状细胞癌和 CCR 是改善 PFS 的有利预后因素(调整后的危险比[HR],0.17 和 0.12;95%置信区间[CI],0.04 至 0.80 和 0.03 至 0.61),仅 CCR 对 OS 的改善有统计学意义(调整后的 HR,0.15;95%CI,0.02 至 0.90)。然而,在 CCR 和 SC 之间,疾病复发的发生率和模式没有差异。

结论

与 SC 相比,CCR 可能更有效地改善生存,并且对于存在远处淋巴结转移的 IVB 期宫颈癌患者,在考虑晚期 RT 相关毒性的情况下,CCR 可以作为一种可行的治疗方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8cc3/3804731/289ee0b3d7c4/crt-45-193-g001.jpg

相似文献

1
Impact of Chemoradiation on Prognosis in Stage IVB Cervical Cancer with Distant Lymphatic Metastasis.
Cancer Res Treat. 2013 Sep;45(3):193-201. doi: 10.4143/crt.2013.45.3.193. Epub 2013 Sep 30.
10
Outcomes and toxicities for the treatment of stage IVB cervical cancer.
Arch Gynecol Obstet. 2012 Jun;285(6):1685-93. doi: 10.1007/s00404-011-2173-6. Epub 2011 Dec 16.

引用本文的文献

1
Management of Stage IVB Cervical Cancer Including the Role of Radiotherapy.
Curr Treat Options Oncol. 2025 May 15. doi: 10.1007/s11864-025-01325-5.
3
Eyelid Metastasis from Cervical Cancer: A Case Report.
Case Rep Oncol. 2023 Nov 7;16(1):1311-1317. doi: 10.1159/000534594. eCollection 2023 Jan-Dec.
5
Outcomes associated with treatment to all sites of disease in patients with stage IVB cancer of the cervix.
Int J Gynecol Cancer. 2023 May 1;33(5):683-691. doi: 10.1136/ijgc-2022-004224.
7
Survival, treatment pattern, and treatment outcome in patients with cervical cancer metastatic to distant lymph nodes.
Front Oncol. 2022 Aug 11;12:952480. doi: 10.3389/fonc.2022.952480. eCollection 2022.
9
Defining the role of high-dose radiation in oligometastatic & oligorecurrent cervical cancer.
Indian J Med Res. 2021 Aug;154(2):303-318. doi: 10.4103/ijmr.IJMR_298_21.

本文引用的文献

1
Pelvic exenteration for recurrent cervical cancer: ten-year experience at National Cancer Center in Korea.
J Gynecol Oncol. 2012 Oct;23(4):242-50. doi: 10.3802/jgo.2012.23.4.242. Epub 2012 Sep 19.
2
Curative chemoradiotherapy in patients with stage IVB cervical cancer presenting with paraortic and left supraclavicular lymph node metastases.
Int J Radiat Oncol Biol Phys. 2012 Nov 1;84(3):741-7. doi: 10.1016/j.ijrobp.2012.01.070. Epub 2012 Aug 14.
3
Radiation therapy with chemotherapy for patients with cervical cancer and supraclavicular lymph node involvement.
J Gynecol Oncol. 2012 Jul;23(3):159-67. doi: 10.3802/jgo.2012.23.3.159. Epub 2012 Jul 2.
4
Major clinical research advances in gynecologic cancer in 2011.
J Gynecol Oncol. 2012 Jan;23(1):53-64. doi: 10.3802/jgo.2012.23.1.53. Epub 2012 Jan 9.
5
Matched-case comparison for the efficacy of neoadjuvant chemotherapy before surgery in FIGO stage IB1-IIA cervical cancer.
Gynecol Oncol. 2010 Nov;119(2):217-24. doi: 10.1016/j.ygyno.2010.06.017. Epub 2010 Aug 11.
9
Chemotherapy for recurrent cervical cancer.
Cancer Treat Rev. 2008 Nov;34(7):603-13. doi: 10.1016/j.ctrv.2008.05.006. Epub 2008 Jul 26.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验